【佳學(xué)基因檢測】腫瘤內(nèi)異質(zhì)性對治療分層的影響

千萬不要做基因檢測合理嗎

挖掘記錄《J Pathol》在?2014 Jan;232(2):264-73發(fā)表了一篇題目為《腫瘤內(nèi)異質(zhì)性對治療分層的影響》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由Andrew Crockford,?Mariam Jamal-Hanjani,?James Hicks,?Charles Swanton等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究內(nèi)容關(guān)鍵詞：

瘤內(nèi)異質(zhì)性,源自患者的異種移植模型,個(gè)性化醫(yī)療。

腫瘤靶向治療基因檢測臨床應(yīng)用結(jié)果

盡管癌癥的診斷和治療取得了進(jìn)展，但大多數(shù)晚期轉(zhuǎn)移性實(shí)體瘤仍然無法治好。個(gè)體腫瘤內(nèi)的差異基因表達(dá)、體細(xì)胞突變狀態(tài)、腫瘤特異性遺傳特征和微環(huán)境選擇壓力對指導(dǎo)治療干預(yù)的預(yù)測分析的成功具有影響。在這篇綜述中，我們討論了遺傳和表型異質(zhì)性的證據(jù)及其對臨床決策的潛在影響。我們強(qiáng)調(diào)了可以改進(jìn)的研究領(lǐng)域，以便更好地對患者治療進(jìn)行分層。我們還討論了患者衍生的腫瘤反應(yīng)模型的預(yù)測潛力，包括腫瘤內(nèi)異質(zhì)性背景下的異種移植和基于細(xì)胞系的系統(tǒng)。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國際數(shù)據(jù)庫描述：

Despite advances in the diagnosis and treatment of cancer, the majority of advanced metastatic solid tumours remain incurable. Differential gene expression, somatic mutational status, tumour-specific genetic signatures and micro-environmental selection pressures within individual tumours have implications for the success of predictive assays to guide therapeutic intervention. In this review we discuss the evidence for genetic and phenotypic heterogeneity and its potential implications for clinical decision making. We highlight areas of research that could be improved in order to better stratify patient treatment. We also discuss the predictive potential of patient-derived models of tumour response, including xenograft and cell line-based systems within the context of intratumour heterogeneity.